Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis

Kathryn L. Pepple, Phoebe Lin

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.

Original languageEnglish (US)
Pages (from-to)1977-1983
Number of pages7
JournalOphthalmology
Volume125
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Interleukin-23
Interleukin-17
Uveitis
Psoriatic Arthritis
Biological Therapy
Immune System Diseases
Psoriasis
Crohn Disease
Autoimmune Diseases
Therapeutics
Monoclonal Antibodies
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis. / Pepple, Kathryn L.; Lin, Phoebe.

In: Ophthalmology, Vol. 125, No. 12, 01.12.2018, p. 1977-1983.

Research output: Contribution to journalReview article

Pepple, Kathryn L. ; Lin, Phoebe. / Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis. In: Ophthalmology. 2018 ; Vol. 125, No. 12. pp. 1977-1983.
@article{14dbe34c56574bc2a233807443d99f60,
title = "Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis",
abstract = "The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.",
author = "Pepple, {Kathryn L.} and Phoebe Lin",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.ophtha.2018.05.014",
language = "English (US)",
volume = "125",
pages = "1977--1983",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis

AU - Pepple, Kathryn L.

AU - Lin, Phoebe

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.

AB - The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.

UR - http://www.scopus.com/inward/record.url?scp=85049355381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049355381&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2018.05.014

DO - 10.1016/j.ophtha.2018.05.014

M3 - Review article

VL - 125

SP - 1977

EP - 1983

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 12

ER -